|
|
Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.
The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.
It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.
Company Strengths
| Particulars | For the year/period ended (Rs in million) | |||
|---|---|---|---|---|
| 30-June-20 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | |
| Total Assets | 46,912.65 | 40,860.39 | 35,235.49 | 29,294.68 |
| Total Revenue | 9,162.89 | 27,724.08 | 21,297.67 | 16,716.82 |
| Profit After Tax | 3,135.90 | 7,728.58 | 4,518.56 | 3,210.51 |
The net proceeds from the IPO will be used for the following purposes:
| Gland Pharma IPO Date | Nov 9, 2020 to Nov 11, 2020 |
| Gland Pharma IPO Face Value | ₹1 per share |
| Gland Pharma IPO Price | ₹1490 to ₹1500 per share |
| Gland Pharma IPO Lot Size | 10 Shares |
| Issue Size | 43,196,968 shares of ₹1 (aggregating up to ₹6,479.55 Cr) |
| Fresh Issue | 8,333,333 shares of ₹1 (aggregating up to ₹1,250.00 Cr) |
| Offer for Sale | 34,863,635 shares of ₹1 (aggregating up to ₹5,229.55 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Company Promoters | Fosun Pharma Industrial Pte. Ltd and Shanghai Fosun Pharmaceutical (Group) Co. Ltd is the company promoters. |
Gland Pharma IPO opens on Nov 9, 2020, and closes on Nov 11, 2020. The Gland Pharma IPO bid date is from Nov 9, 2020 10.00 A.M. to Nov 11, 2020 5.00 P.M. The Cut-off time for UPI Mandate confirmation is 5 PM on the issue closing day.
| Event | Date |
|---|---|
| Gland Pharma IPO Opening Date | Nov 9, 2020 |
| Gland Pharma IPO Closing Date | Nov 11, 2020 |
| Basis of Allotment | Nov 17, 2020 |
| Initiation of Refunds | Nov 18, 2020 |
| Credit of Shares to Demat | Nov 19, 2020 |
| Gland Pharma IPO Listing Date | Nov 20, 2020 |
The Gland Pharma IPO lot size is 10 shares. A retail-individual investor can apply for up to 13 lots (130 shares or ₹195,000).
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 10 | ₹15,000 |
| Retail (Max) | 13 | 130 | ₹195,000 |
| Pre Issue Share Holding | 74% |
| Post Issue Share Holding | 58% |
Related Articles
No doubt that currently, the pharma sector is attracting investors following COVID-19 pandemic and the search of remedies for it globally. This company has posted good performance for the last three fiscals and spectacular numbers for Q1 of FY21, but will it sustain going forward is a major concern in the present context of negative sentiment for China connections globally. Based on P/BV and P/E parameters, the issue appears fully priced. Considering all these, though it sounds lucrative bet for the long term, risk savvy, cash surplus investors may consider investment at their own risk in this China connected IPO. Read detail review...
The Gland Pharma IPO is subscribed 2.06 times on Nov 11, 2020 6:00:01 PM. The public issue subscribed 0.24 times in the retail category, 6.40 times in the QIB category, and 0.51 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 6.40 |
| NII | 0.51 |
| Retail | 0.24 |
| Total | 2.06 |
| Listing Date | Friday, November 20, 2020 |
| BSE Script Code | 543245 |
| NSE Symbol | GLAND |
| Listing In | B Group of Securities |
| ISIN | INE068V01023 |
| IPO Price | ₹1500 per share |
| Face Value | ₹1 per share |
|
|
|
Gland Pharma Limited
Sy. No. 143 - 148, 150 and 151,
Near Gandi Maisamma 'X' Roads, D.P. Pally,Dundigal
Medchal-Malkajgiri District, Hyderabad
Phone: +91 40 3051 0999
Email: investors@glandpharma.com
Website: http://www.glandpharma.com
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: glandpharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/
Gland Pharma IPO is a main-board IPO of 43,196,968 equity shares of the face value of ₹1 aggregating up to ₹6,479.55 Crores. The issue is priced at ₹1490 to ₹1500 per share. The minimum order quantity is 10 Shares.
The IPO opens on Nov 9, 2020, and closes on Nov 11, 2020.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Gland Pharma IPO using UPI as a payment gateway. Zerodha customers can apply in Gland Pharma IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Gland Pharma IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Gland Pharma IPO opens on Nov 9, 2020 and closes on Nov 11, 2020.
Gland Pharma IPO lot size is 10 Shares and the minimum order quantity is .
You can apply in Gland Pharma IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Edelweiss, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Gland Pharma IPO will be done on Nov 17, 2020, and the allotted shares will be credited to your demat account by Nov 19, 2020. Check the Gland Pharma IPO allotment status.
Ashish Khater
Ashish Khater
Useful Articles
30 days brokerage free trading
Free - Relationship Manager
Free - Classroom Training
|
|
IPO Guru (1300+ Posts, 1200+ Likes)
Top Contributor (200+ Posts, 100+ Likes)
IPO Mentor (500+ Posts, 1000+ Likes)
